Key result
Multifactorial cardiovascular risk intervention sharply reduces CVD risk in patients with diabetes.
Why the study?
Cardiovascular disease causes up to 80% of excess mortality in patients with diabetes, and the impact of traditional risk factors is amplified in this population.
Does rigorous treatment of blood pressure, dyslipidemia, and platelet hyperaggregability reduce cardiovascular disease risk in patients with diabetes mellitus?
Does rigorous treatment of blood pressure, dyslipidemia, and platelet hyperaggregability reduce cardiovascular disease risk in patients with diabetes mellitus?
Rigorous management of cardiovascular risk factors, particularly with RAS inhibitors and statins, is highly beneficial for reducing CVD risk in patients with diabetes.
Answers are grounded in this paper and cite their sources.
Supports intensive risk factor control in diabetes but should not yet change practice; leaves open confirmation in randomized trials.
Diabetes mellitus is increasing throughout the world. Cardiovascular disease (CVD) accounts for up to 80% of excess mortality in this high-risk population. Patients with diabetes have the same CVD risk factors as those people without diabetes. However, these risk factors are much more powerful in diabetic patients. CVD risk is especially high for diabetic women, and premenopausal diabetic women lose all the protection normally afforded to them by female sex hormones. Controlled clinical trials have clearly demonstrated that rigorous treatment of blood pressure, dyslipidemia and platelet hyperaggrebility strikingly reduces CVD risk in diabetic patients. Strategies directed at interrupting the renin-angiotensin system (both tissue and systemic systems) and the use of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors have proven to be especially beneficial for this high-risk population.
No takes yet. Share an insight, caveat, or question.
Kassab et al. (2001) conducted a review in Diabetes mellitus. Rigorous treatment of blood pressure, dyslipidemia, and platelet hyperaggregability was evaluated on Cardiovascular disease (CVD) risk.
Synapse has enriched 10 related papers. Consider them for comparative context: